한글목차

세계의 항체약물접합체 시장 규모는 2024년에 77억 5,000만 달러에 달하며, 예측 기간에는 2030년까지 CAGR 6.25%로 인상적인 성장이 예측됩니다. 항체약물접합체(ADC) 시장은 제약 및 생명공학 산업에서 역동적이고 빠르게 발전하고 있는 분야로, ADC는 단클론 항체(mAb)의 특이성과 세포독성 약물의 효능을 결합한 획기적인 암 표적 치료제입니다. 이러한 시너지 효과로 강력한 항암제를 암세포에 직접 정확하게 전달하면서 건강한 조직을 보존하고 기존 화학요법의 부작용을 최소화할 수 있으며, ADC 시장은 몇 가지 중요한 요인에 의해 크게 성장하고 있습니다. 첫째, 전 세계에서 다양한 암종에서 암의 유병률이 증가함에 따라 혁신적이고 효과적인 치료법에 대한 필요성이 증가하고 있으며, ADC는 치료 옵션이 제한적인 환자들에게 개선된 치료 결과를 제공하는 유망한 솔루션으로 부상하고 있습니다.

주요 시장 성장 촉진요인

암 발병률 증가

주요 시장 이슈

제한된 유형의 종양

주요 시장 동향

다양한 암 적응증에 대한 ADC 후보물질 파이프라인 증가

목차

제1장 개요

제2장 조사 방법

제3장 개요

제4장 고객의 소리

제5장 세계의 항체약물접합체 시장 전망

• 시장 규모·예측
  • 금액별
• 시장 점유율·예측
  • 유형별(모노클로널 항체, 링커, 약물/독소, 기타)
  • 용도별(혈액암, 유방암, 난소암, 폐암, 뇌종양, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 항체약물접합체 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 북미 : 국가별 분석
  • 캐나다
  • 멕시코

제7장 유럽의 항체약물접합체 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 유럽 : 국가별 분석
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 항체약물접합체 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 아시아태평양 : 국가별 분석
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 항체약물접합체 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 남미 : 국가별 분석
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 항체약물접합체 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 합병과 인수

제13장 세계의 항체약물접합체 시장 : SWOT 분석

제14장 경쟁 구도

• Novartis AG
• F. Hoffmann-La Roche Ltd
• Takeda Pharmaceutical Company Limited
• Pfizer Inc.
• Seattle Genetics Inc
• Genentech Inc
• Immunogen Inc
• Immunomedics Inc
• Progenics Pharmaceuticals Inc
• Bayer HealthCare Pharmaceuticals Inc

제15장 전략적 제안

제16장 조사회사 소개·면책사항

영문목차

Global Antibody Drug Conjugates Market was valued at USD 7.75 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.25% through 2030. The Antibody Drug Conjugates (ADCs) Market is a dynamic and rapidly evolving segment within the pharmaceutical and biotechnology industries. ADCs represent a groundbreaking class of targeted cancer therapies that combine the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic drugs. This synergy enables precise delivery of potent anticancer agents directly to cancer cells while sparing healthy tissue, thereby minimizing side effects associated with traditional chemotherapy. The market for ADCs has witnessed substantial growth driven by several key factors. Firstly, the increasing prevalence of cancer, both globally and across various cancer types, underscores the critical need for innovative and effective treatments. ADCs have emerged as a promising solution, offering improved therapeutic outcomes for patients with limited treatment options.

Key Market Drivers

Growing prevalence of cancer

The growing prevalence of cancer serves as a compelling driver for the Global Antibody Drug Conjugates (ADCs) Market. Cancer has reached alarming proportions worldwide, with millions of new cases diagnosed annually. ADCs, a class of targeted cancer therapies, offer a ray of hope in the battle against this devastating disease. The rise in cancer cases underscores the unmet medical need for more effective and less toxic treatments. ADCs precisely deliver potent anticancer drugs to tumor cells, minimizing damage to healthy tissue, and hence are increasingly sought after. For instance, according to WHO, in 2022, an estimated 20 million new cancer cases and 9.7 million cancer-related deaths were reported globally. By 2050, the cancer burden is expected to rise by 77%, placing greater pressure on health systems and communities. In the WHO Eastern Mediterranean Region, over 788,000 cancer cases were diagnosed in 2022. This number is projected to double to 1.57 million by 2045 due to population growth and widespread risk factors, including tobacco use, obesity, physical inactivity, unhealthy diets, and air pollution. Addressing these risks is crucial to mitigating the rising cancer burden in the region.

Key Market Challenges

Limited Tumor Types

Limited tumor types targeted by Antibody Drug Conjugates (ADCs) pose a significant challenge in the global market. ADCs are highly specific, and their effectiveness depends on the presence of specific antigens on cancer cells. This restricts their applicability to a select range of tumor types, leaving many cancers without effective ADC treatment options. Developing ADCs for a broader spectrum of tumors requires identifying suitable target antigens and investing in extensive research and development. Additionally, regulatory approval for new ADCs can be time-consuming and costly. Overcoming the limitation of tumor types is crucial to expand the market's reach and impact in the oncology field.

Key Market Trends

Growing pipeline of ADC candidates for various cancer indications.

The growing pipeline of Antibody Drug Conjugate (ADC) candidates for various cancer indications is a noteworthy trend in the global ADC market. This trend reflects the increasing interest and investment in ADC research and development, driven by several factors: The ADC field has witnessed a surge in research and investment, leading to the development of a diverse range of ADC candidates. These candidates target various cancer indications, including solid tumors and hematological malignancies. This expansion of the therapeutic landscape is a response to the unmet medical needs across different cancer types. ADCs are known for their precision in targeting cancer cells while sparing healthy tissues. Advancements in genomics and biomarker discovery have enabled the identification of specific antigens and genetic profiles associated with different cancer types. This knowledge allows for the design of ADCs tailored to individual cancer subtypes, promoting personalized treatment approaches. The development of ADCs often goes hand in hand with research into combination therapies. Combining ADCs with other targeted therapies, immunotherapies, or standard chemotherapy regimens can enhance treatment efficacy. This trend aligns with the growing interest in combination approaches to address complex cancer biology. As cancer cells can develop resistance to single-agent therapies, researchers are exploring ADCs as a strategy to overcome resistance mechanisms. This has led to the development of ADCs that target specific resistance pathways or employ alternative mechanisms of action.

Key Market Players

• Novartis AG
• F. Hoffmann-La Roche Ltd
• Takeda Pharmaceutical Company Limited
• Pfizer Inc.
• Seattle Genetics Inc
• Genentech Inc
• Immunogen Inc
• Immunomedics Inc
• Progenics Pharmaceuticals Inc
• Bayer HealthCare Pharmaceuticals Inc

Report Scope:

In this report, the Global Antibody Drug Conjugates Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antibody Drug Conjugates Market, By Type:

• Monoclonal Antibodies
• Linker
• Drug/Toxin
• Others

Antibody Drug Conjugates Market, By Application:

• Blood Cancer
• Breast Cancer
• Ovarian Cancer
• Lung Cancer
• Brain Tumor
• Others

Antibody Drug Conjugates Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Antibody Drug Conjugates Market.

Available Customizations:

Global Antibody Drug Conjugates market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antibody Drug Conjugates Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Types (Monoclonal Antibodies, Linker, Drug/Toxin, Others)
  • 5.2.2. By Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Antibody Drug Conjugates Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Types
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Antibody Drug Conjugates Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Types
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Antibody Drug Conjugates Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Types
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Antibody Drug Conjugates Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Types
      • 6.3.3.2.2. By Application

7. Europe Antibody Drug Conjugates Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Types
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Antibody Drug Conjugates Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Types
      • 7.3.1.2.2. By Application
  • 7.3.2. United Kingdom Antibody Drug Conjugates Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Types
      • 7.3.2.2.2. By Application
  • 7.3.3. Italy Antibody Drug Conjugates Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Types
      • 7.3.3.2.2. By Application
  • 7.3.4. France Antibody Drug Conjugates Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Types
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Antibody Drug Conjugates Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Types
      • 7.3.5.2.2. By Application

8. Asia-Pacific Antibody Drug Conjugates Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Types
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Antibody Drug Conjugates Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Types
      • 8.3.1.2.2. By Application
  • 8.3.2. India Antibody Drug Conjugates Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Types
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Antibody Drug Conjugates Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Types
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Antibody Drug Conjugates Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Types
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Antibody Drug Conjugates Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Types
      • 8.3.5.2.2. By Application

9. South America Antibody Drug Conjugates Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Types
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Antibody Drug Conjugates Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Types
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Antibody Drug Conjugates Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Types
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Antibody Drug Conjugates Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Types
      • 9.3.3.2.2. By Application

10. Middle East and Africa Antibody Drug Conjugates Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Types
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Antibody Drug Conjugates Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Types
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Antibody Drug Conjugates Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Types
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Antibody Drug Conjugates Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Types
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisition

13. Global Antibody Drug Conjugates Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Novartis AG
  • 14.1.1. Business Overview
  • 14.1.2. Treatment Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Key Personnel
  • 14.1.5. SWOT Analysis
• 14.2. F. Hoffmann-La Roche Ltd
• 14.3. Takeda Pharmaceutical Company Limited
• 14.4. Pfizer Inc.
• 14.5. Seattle Genetics Inc
• 14.6. Genentech Inc
• 14.7. Immunogen Inc
• 14.8. Immunomedics Inc
• 14.9. Progenics Pharmaceuticals Inc
• 14.10.Bayer HealthCare Pharmaceuticals Inc

15. Strategic Recommendations

16. About Us & Disclaimer